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Background: Viral load monitoring is used as an important biomarker for diagnosing treatment 
failure in patients with HIV infection/AIDS. Ethiopia has started targeted viral load monitoring. 
However, factors leading to virological failure are not well understood and studied. Thus, the 
aim of this study was to identify the determinants of virological failure among HIV-infected 
patients on highly active antiretroviral therapy at the University of Gondar Referral Hospital, 
Northwest Ethiopia.
Methods: A case–control study was conducted from May to June 2015. Cases were subjects 
who had already experienced virological failure; controls were those without virological failure. 
Data were extracted from 153 cases and 153 controls through chart review. A multivariate logistic 
regression analysis was carried out to identify factors associated with virological failure, and 
variables with a p-value <0.05 were considered statistically significant.
Results: In this study, higher odds of virological failure was observed among patients aged 
<35 years (adjusted odds ratio [AOR] =2.52, 95% CI: 1.33, 4.77), who had had CD4+ count 
<200 cells/mm3 (AOR=9.03, 95% CI: 4.40, 18.50), showed poor adherence to antiretroviral 
therapy (ART) (AOR=15.80, 95% CI: 6.90, 36.50), and had taken ART for longer durations of 
25–47 months (AOR=3.00, 95% CI: 1.10, 8.40) and ≥48 months (AOR=6.70, 95% CI: 2.70, 
16.60).
Conclusion: This study showed that patients aged <35 years and with recent low CD4 count, 
poor adherence to treatment, and longer exposure to ART were positively and significantly 
associated with virological treatment failure. Therefore, evidence-based intervention should be 
implemented to improve adherence to ART, which in turn helps to boost immunity (CD4) and 
suppresses viral replication and load. Moreover, attention should be given to younger patients 
who have had ART for longer periods.
Keywords: HIV, virological failure, highly active antiretroviral therapy, case–control study, 
Ethiopia
Introduction
HIV infection/AIDS has continued to be one of the top priorities of the health sector 
program of the Ethiopian government.1 Of the estimated 593,400 adults living with 
HIV, 298,512 were on treatment by the end of 2013. More than 45,200 people died 
due to AIDS in the same year.2
Highly active antiretroviral therapy (HAART), the lifesaving treatment for patients 
with HIV/AIDS, is an important component of the overall treatment plan.3 Since its 
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introduction, the impact of HIV infection has significantly 
decreased.4 The goal of the treatment is to suppress virus 
replication for as long as possible, restore and/or preserve 
immune function, improve quality of life, and reduce HIV-
related morbidity and mortality.5–7 But this has not always 
been apparent as many of the patients experience deteriora-
tion and develop treatment failure, which can be explained 
by virological, clinical, or immunological causes or all of 
these because they do not behave according to expectations.7
Virological failure, which is a more informative treatment 
failure, is a common problem that an HIV patient faces after 
starting treatment.8,9 Current guidelines recommend that once 
patients start treatment, virological failure should not exceed 
10%.8,10 However, studies show that virological failure is 
much higher than expected,11–16 and viral replication continues 
to be a major challenge among patients living with HIV.11,17 
Patients who experienced virological failure were found 
to have an increased risk of clinical progression to AIDS 
and mortality when compared with patients with complete 
virological response.17 Previous studies revealed that various 
factors were associated with virological failure. Accordingly, 
baseline CD4 count,15,17–19 younger age,12,14,20,21 longer time on 
HAART,15,16,20 poor adherence to treatment,20–23 and last lower 
CD4 count16,24 were associated with virological failure. On the 
other hand, extra baseline weight was negatively associated 
with virological failure.
Identifying and managing determinants of virological 
failure are of paramount importance to achieve a high treat-
ment success rate and improve the quality of life. However, 
there is limited evidence on the determinants of virological 
failure among HIV-infected patients on HAART in Ethiopia 
and in the study area. Thus, this study aimed to identify the 
determinants of virological failure among HIV-infected 
patients on HAART at the University of Gondar Referral 
Hospital, Northwest Ethiopia.
Methods
Study design and setting
A hospital-based case–control study was conducted from 
May to June 2015 at the University of Gondar Referral Hospi-
tal. This hospital is a pioneer health facility located in Gondar 
district 748 km from Addis Ababa, the capital of Ethiopia, 
and provides health care services to >5 million residents 
of Northwest Ethiopia. The chronic HIV care center was 
launched in 2003 and free ART started in 2006. The service 
is provided in the Adult, Pediatric ART, and Prevention of 
Mother to Child Transmission (PMTCT) clinics. Ever since 
the launching of the care, about 12,470 HIV-infected clients 
were enrolled in the ART clinic. Out of these, 8,220 started 
ART and 5,138 are on HAART currently.
Study participants and sample size 
determination
All HIV-infected adults aged ≥15 years and had been enrolled 
for ART with documented viral load results from 2010 to 
2015 were included in the study. However, clients who had a 
follow-up of <6 months at the University of Gondar Referral 
Hospital were excluded.
All HIV-infected adults whose plasma viral load of ≥1,000 
copies/mL in 2 consecutive viral load measurements in a 
3-month interval after 6 months of starting a new ART regi-
men were defined as cases (virological failure) with adherent 
support, while study participants with a viral load level of 
<1,000 copies/mL were considered as controls.10
Sample size was determined using Epi Info™ 7 Stat-
Calc by taking the key predictor of virological failure (poor 
adherence) from a previous study.20 Therefore, the calculated 
sample size was 208 (104 cases and 104 controls). However, 
to improve the power of the study, all of the cases (153) 
and comparable controls (153) were included in the study. 
Controls were selected by using simple random sampling 
techniques.
Data collection tools and procedure
Data were extracted from patient charts using a pretested 
structured checklist. Accordingly, all charts containing 
detailed information about patients who were on HAART 
from 2010 to 2015 were reviewed. Six health professionals 
trained for 2 days collected the data. The principal investi-
gator and the supervisor closely monitored the whole data 
collection process on a daily basis. Adherence to treatment 
was determined using the World Health Organization (WHO) 
definition in the follow-up chart. Thus, poor adherence to 
treatments is defined as patients taking ≤95% of the recom-
mended regimens.7
Statistical analysis
Data were entered into Epi Info version 7 and analyzed using 
SPSS version 20. Descriptive statistics, including mean 
values and frequencies, were used to describe demographic, 
clinical, hematologic, and medication-related characteristics 
of patients. Bivariate analysis was carried out for all indepen-
dent variables with an outcome variable. Using variables with 
a p-value of up to 0.2, according to the bivariate analysis, a 
multivariate logistic regression analysis was carried out to 
identify the independent determinants of virological failure. 
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The Hosmer–Lemeshow goodness-of-fit test for the model 
was also checked. Finally, variables that had significant 
associations with virological failure were identified based 
on the odds ratio (OR) with a 95% CI and p-values <0.05.
Ethical considerations
Informed consent was waived by the Institutional Ethical 
Review Board of the University of Gondar and the Chief 
Clinical Officer of the University of Gondar Referral Hos-
pital for this retrospective chart review, as all the data were 
 de-identified. The confidentiality of information obtained 
from each study participant was guaranteed by omitting 
names or any personal identifiers. Moreover, the collected 
data were kept safe throughout the whole process of the 
research work to limit data accessibility to a third party.
Results
Sociodemographic characteristics
At baseline, the mean age of the cases and the controls was 
32 years (SD: ±7 years) and 36 years (SD: ±10 years), respec-
tively. Moreover, 80 (53.6%) of cases and 79 (51.6%) of the 
controls were females; 138 (90.2%) of the cases and 132 
(86.3%) of the controls were Orthodox Christians. More than 
three-quarters (75.8% and 79.7%) of the cases and controls, 
respectively, were urban dwellers (Table 1).
Clinical-related characteristics
Among the participants, 121 (79.1%) cases and 111 (72.5%) 
controls were classified as stages III and IV at baseline. 
Moreover, 33 (21.6%) of the cases and 20 (13.1%) of the 
controls developed tuberculosis (TB) before initiation of 
HAART, while one-quarter (26.1% and 28.8%) of the cases 
and controls, respectively, acquired TB after enrollment in 
HAART (Table 2).
Antiretroviral medication-related 
characteristics
Almost half (49.7%) of the cases and only 12 (7.8%) of the 
controls had history of poor adherence to treatment. Nearly 
three-fourths (71.2%) of the cases and half (49.1%) of the 
controls were on HAART for ≥48 months (Table 3).
Hematologic profile of the study 
participants
In this study, 135 (88.2%) of the cases and 121 (78.9%) of 
the controls had <200 cells/mm3 CD4 count at baseline, while 
125 (81.7%) of the cases and 74 (48.4%) of the controls had 
CD4 count <200 cells/mm3 at the previous visit.
Factors associated with HIV virological 
failure
The bivariate logistic regression analysis showed that age, 
educational status, occupation, ART medication adherence, 
TB coinfection, baseline WHO clinical stage, current body 
mass index (BMI), first-line ART, duration on ART, baseline 
and recent CD4 count, current WBC count, and hemoglobin 
level were associated with antiretroviral virological failure.
After adjustment for possible effects of confounding 
variables, patients aged <35 years, with recent CD4 count 
<200 cells/mm3, poor adherence to ART, and longer dura-
tion of ART enrollment were significantly associated with 
virological failure.
The likelihood of developing virological failure for 
patients aged <35 years was 2.5 times (adjusted OR [AOR] 
=2.52, 95% CI: 1.33, 4.77) as likely as compared with their 
older counterparts. Patients who had had a recent CD4 count 
of <200 cells/mm3 were 9 times (AOR=9.03, 95% CI: 4.40, 
18.50) as likely to have virological failure as those with 
higher CD4 counts. Patients who were poorly adherent to 
their ART were 16 times (AOR=15.80, 95% CI: 6.90, 36.50) 
Table 1 Sociodemographic characteristics of HIV-infected 
patients treated at the University of Gondar Referral Hospital: 
2010–2015
Variables Cases Controls
Frequency (%) Frequency (%)
Age, years
<35 99 (64.7) 73 (47.7)
≥35 54 (35.3) 80 (52.3)
Sex
Male 71 (46.4) 74 (48.4)
Female 82 (53.6) 79 (51.6)
Residence
Urban 116 (75.8) 122 (79.7)
Rural  37 (24.2)  31 (20.3)
Marital status
Never married 35 (22.9) 31 (20.3)
Married 65 (42.5) 47 (30.7)
Othersa 53 (34.6) 75 (49.0)
Educational level
No schooling 42 (27.5) 34 (22.2)
Primary school 55 (35.9) 34 (22.2)
Secondary school 56 (36.6) 85 (55.6)
Religion
Orthodox 138 (90.2) 132 (86.3)
Othersb 15 (9.8) 21 (13.7)
Occupation
Not employed 48 (31.4) 50 (32.7)
Government employed 24 (15.7) 42 (27.5)
Self–employed 41 (26.8) 31 (20.2)
Daily laborer 40 (26.1) 30 (19.6)
Notes: aDivorced, separated, or widowed; bMuslim or Protestant.
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as likely to have virological failure as compared to those who 
were adherent to their treatment. Patients who took ART for 
24–47 months and for >48 months were 3 times (AOR=3.00, 
95% CI: 1.10, 8.40) and 7 times (AOR=6.7, 95% CI: 2.7, 
16.60), respectively, as likely to have virological failure as 
those who took the treatment for 6–24 months (Table 4).
Discussion
This study investigated the determinants of ART virologi-
cal failure and revealed that patients aged <35 years, with 
recent low CD4 count (<200 cells/mm3), poor adherence to 
treatment, and longer duration on HAART enrollment were 
found to have increased odds of virological failure.
In this study, patients aged <35 years were associated 
with virological failure. Similar findings were reported from 
Nyanza region, Kenya,12 Cameroon,14 Mozambique,20 and 
France,21 where the likelihood of developing ART virological 
failure was higher among younger patients. This might be 
due to differences in lifestyles, as most of the younger adults 
commonly suffered from less healthy personality traits and 
were more vulnerable to substance abuse. Moreover, they 
had less emotional stability to cope with the social stigma, 
discrimination, and the adverse consequences of the disease 
itself. This suggests that depression, anxiety, and unhealthy 
behaviors could negatively affect dietary intake and treatment 
outcomes of clients.25
Patients with a recent low CD4 count were 9 times as 
likely to develop virological failure as those with higher CD4 
count (>200 cells/mm3). The finding was consistent with 
those of studies conducted in Swaziland16 and northwestern 
Uganda.24 It is well known that CD4 count has an inverse rela-
tionship with viral replication and load. As patients’ immune 
status becomes compromised, the rate of viral replication 
increases compared to their immune-competent counterparts. 
Furthermore, clients with compromised immunity are more 
vulnerable to different opportunistic infections that sustain 
the vicious cycle of immunity and viral replication.6
Adherence to ART was also an important determinant 
of virological failure. Patients with poor medication adher-
ence were 16 times as likely to develop virological failure 
as patients with good adherence. The finding was consistent 
with those of studies conducted in Mozambique,20 France,21 
China,22 and Guangxi, China,23 where poor medication adher-
ence was the main risk factor for virological failure. It is 
evident that individuals missing 3 doses of ART per month 
are associated with an increased risk of drug resistance and 
reduced immunity.6 This results in the loss of the opportunity 
to suppress viral replication and leads to virological failure.7
Table 2 Behavioral and clinical-related information among 
HIV-positive adults who have had follow-up at the University of 
Gondar Referral Hospital: 2010–2015
Variables Cases Controls
Frequency (%) Frequency (%)
Baseline BMI, kg/m2
<16.5 22 (14.4) 19 (11.8)
16.5–18.49 48 (31.4) 49 (32.2)
≥18.5 83 (54.2) 85 (55.9)
Current BMI, kg/m2
<16.50 28 (18.3) 17 (10.5)
16.50–18.49 27 (17.6) 28 (18.4)
≥18.50 98 (64.1) 108 (71.1)
WHO clinical stage
Stages I and II 32 (20.9) 42 (27.5)
Stages III and IV 121 (79.1) 111 (72.5)
History of TB
Before ART 33 (21.6) 20 (13.1)
After ART 40 (26.1) 44 (28.8)
Duration with HIV, months
6–24 9 (5.9) 28 (18.3)
24–47 30 (19.6) 46 (30.1)
≥48 114 (74.5) 79 (51.6)
History of substance use
Yes 27 (17.6) 35 (22.9)
No 126 (82.4) 118 (77.1)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; TB, 
tuberculosis.
Table 3 Antiretroviral medication-related information among 
HIV-positive adults who have had follow-up at the University of 
Gondar Referral Hospital: 2010–2015
Variables Cases Controls
Frequency (%) Frequency (%)
Adherence to treatment
Good 77 (50.3) 141 (92.2)
Poor 76 (49.7) 12 (7.8)
CPT use
Yes 142 (92.8) 139 (90.8)
No 11 (7.2) 14 (9.2)
First-line ART regimen
AZT based 48 (31.4) 78 (51.0)
TDF based 40 (26.1) 37 (24.2)
D4T based 65 (42.5) 38 (24.8)
Change of ARV regimen or individual drugs
Yes 73 (47.7) 72 (47.1)
No 80 (52.3) 81 (52.9)
ART regimen at the time of VL test
TDF based 67 (43.8) 63 (41.2)
AZT based 86 (56.2) 90 (58.8)
ART duration, months
6–24 13 (8.5) 38 (24.8)
24–47 31 (20.3) 40 (26.1)
≥48 109 (71.2) 75 (49.1)
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; AZT, 
azidothymidine; BMI, body mass index; CPT, cotrimoxazole preventive therapy; D4T, 
stavudine; TB, tuberculosis; TDF, tenofovir disoproxil fumarate; VL, viral load.
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Duration of ART was a significant factor associated 
with virological failure. This study showed that the likeli-
hood of virological failure was 3 and 7 times more among 
patients who took ART for ~24–47 months and ≥48 months, 
 respectively, compared to patients who took the treatment for 
6–24 months. This finding is supported by studies conducted 
in Gabon,15 Swaziland,16 and Mozambique.20 The possible 
reason might be that as the duration of ART increased, the 
Table 4 Determinants of ART virological failure among HIV-positive adults who had follow-up at the University of Gondar Referral 
Hospital: 2010–2015
Variables Virological failure COR (95% CI) AOR (95% CI)
Cases, n (%) Controls, n (%)
Age, years
<35 99 (64.7) 73 (47.7 2.00 (1.27, 3.18)* 2.52 (1.33,4.77)*
≥35 54 (35.3) 80 (52.3) 1 –
Educational status
No schooling 42 (27.5) 34 (22.2) 1 –
Primary 55 (35.9) 34 (22.2) 1.88 (1.07, 3.23)* –
Secondary 56 (36.6) 85 (55.6) 2.56 (1.42,4.23)* –
Occupation
Unemployed 48 (31.4) 50 (32.7) 1 –
Employed 24 (15.7) 42 (27.5) 0.59 (0.31, 1.13) –
Self-employed 41 (26.8) 31 (20.3) 1.38 (0.75, 2.54) –
Daily laborer 40 (26.1) 30 (19.6) 1.39 (0.75, 2.57) –
WHO clinical stage
Stages I and II 32 (20.9) 42 (27.5) 1 –
Stages III and IV 121 (79.1) 111 (72.5) 1.43 (0.84,2.42) –
Adherence
Good 77 (50.3) 141 (92.2) 1 –
Poor 76 (49.7) 12 (7.8) 12.4 (6.26, 24.9)* 15.8 (6.90,36.50)*
History of TB
No TB 80 (52.3) 89 (58.2) 1 –
Before ART 33 (21.6) 20 (13.1) 1.84 (0.976, 3.45) –
After ART 40 (26.1) 44 (28.7) 1.01 (0.60, 1.71) –
First-line ART regimen
D4T based 65 (42.5) 38 (24.8) 0.36 (0.21, 0.62)* –
AZT based 48 (31.4) 78 (51.0) 0.63 (0.34, 1.14) –
TDF based 40 (26.1) 37 (24.2) 1 –
Duration on ART, months
6–24 13 (8.5) 38 (24.8) 1 1
24–47 31 (20.3) 40 (26.1) 2.26 (1.03, 4.97)* 3.00 (1.10, 8.40)*
≥48 109 (71.2) 75 (49.1) 4.25 (2.12, 8.52)* 6.7 (2.7, 16.60)*
Current BMI, kg/m2
<16.5 28 (18.3) 17 (10.5) 1.92 (0.98, 3.78) –
16.5–18.49 27 (17.6) 28 (18.4) 1.06 (0.58,1.97) –
≥18.5 98 (64.1) 108 (71.1) 1 –
Current WBC count, cells/mm3
<4,000 59 (37.8) 36 (23.8) 1.94 (1.18, 3.20)* –
≥4,000 94 (62.2) 117 (76.2) 1 –
Current hemoglobin level, g/dL
<12 37 (24.2) 24 (15.9) 1.68 (0.95, 2.99) –
≥12 116 (75.8) 129 (84.1) 1 –
Baseline CD4 count, cells/mm3
<200 135 (88.2) 121 (79.1) 2.00 (1.07, 3.75)* –
≥200 18 (11.8) 32 (20.9) 1 –
Current CD4 count, cells/mm3
<200 125 (81.7) 74 (48.4) 4.77 (2.84, 8.00)* 9.03 (4.40,18.50)*
≥200 28 (18.3) 79 (51.6) 1 1
Notes: *Significant at a p-value of <0.05; Hosmer–Lemeshow test =0.702.
Abbreviations: AOR, adjusted odds ratio; ART, antiretroviral therapy; AZT, azidothymidine; BMI, body mass index; COR, crude odds ratio; D4T, stavudine; TB, 
tuberculosis; TDF, tenofovir disoproxil fumarate.
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likelihood of developing poor adherence and drug interrup-
tion, as well as drug side effects, also increased.6 All these 
factors might have led to virological failure.
Conclusion
This study showed that age <35 years, low CD4 count, poor 
adherence to treatment, and higher duration of taking ART 
were positively and significantly associated with virological 
failure. Therefore, efforts should be strengthened to improve 
adherence to ART, which helps to boost immunity and sup-
press viral replication and load. Moreover, more attention 
should be given to younger patients who have taken ART for 
a prolonged duration.
Acknowledgments
We are indebted to the University of Gondar for permission 
to conduct the study. Our gratitude also goes to the data col-
lectors and supervisors who participated in the study.
Author contributions
All authors contributed toward data analysis, drafting and 
critically revising the paper and agree to be accountable for 
all aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. HIV/AIDS in Ethiopia: An Epidemiological Synthesis. Addis Ababa, 
Ethiopia: Federal HIV/AIDS Prevention and Control Office; 2014.
 2. Country Progress Report on The HIV Response. Addis Ababa, Ethiopia: 
Federal Democratic Republic of Ethiopia; 2014.
 3. UNHCR. Clinical Guidelines for Antiretroviral Therapy Management 
for Displaced Populations Southern Africa. Geneva, Switzerland: 
Southern African HIV Clinicians Society; 2007.
 4. HIV/AIDS Progress in 2014. UNECA Compound. Addis Abeba, Ethio-
pia: World Health Organization Ethiopia Country Office; 2015.
 5. Churchill D, Waters L, Ahmed N, et al. British HIV Association 
guidelines for the treatment of HIV-1-positive adults with antiretroviral 
therapy 2015. Br HIV Assoc. 2015;17(S4):s2–s104.
 6. AIDSinfo. Guidelines for the Use of Antiretroviral Agents in HIV-1- 
Infected Adults and Adolescents. 2016.
 7. NACO. ART Guidelines for HIV-Infected Adults and Adolescents. 
Ministry of Health and Family Welfare Government of India; 2013.
 8. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for 
Treating and Preventing HIV Infection. Recommendations for a Public 
Health Approach; 2016.
 9. WHO. To the 2013 Consolidated Guidelines on the Use of Antiretroviral 
Drugs for Treating and Preventing HIV Infection. Geneva, Switzerland: 
Recommendations for a Public Health Approach; 2014.
 10. WHO. Guideline on When to Start Antiretroviral Therapy and on Pre-
Exposure Prophylaxis for HIV. 2015.
 11. Leng X, Liang S, Ma Y, et al. HIV virological failure and drug resistance 
among injecting drug users receiving first-line ART in China. BMJ 
Open. 2014;4(10):e005886.
 12. Sang RKA, Miruka FO. Factors associated with virologic failure 
amongst adults on antiretroviral therapy in Nyanza Region, Kenya. 
IOSR J Dent Med Sci. 2016;15(7):108–121.
 13. Vidal JE, Song ATW, Matos ML, et al. High rate of virologic suppres-
sion with darunavir/ritonavir plus optimized background therapy among 
highly antiretroviral-experienced HIV-infected patients: results of a pro-
spective cohort study in São Paulo, Brazil. Braz J Infect Dis. 2013;17(1): 
41–47.
 14. Meriki HD, Tufon KA, Afegenwi MH, et al. Immuno-haematologic 
and virologic responses and predictors of virologic failure in HIV-1 
infected adults on first-line antiretroviral therapy in Cameroon. Infect 
Dis Poverty. 2014;3:5.
 15. Liégeois F, Vella C, Eymard-Duvernay S, et al. Virological failure 
rates and HIV-1 drug resistance patterns in patients on first-line 
antiretroviral treatment in semirural and rural Gabon. J Int AIDS Soc. 
2012;15(2):17985.
 16. Jobanputra K, Parker LA, Azih C, et al. Factors associated with viro-
logical failure and suppression after enhanced adherence counselling, 
in children, adolescents and adults on antiretroviral therapy for HIV in 
Swaziland. PLoS One. 2015;10(2):e0116144.
 17. Kitchen CM, Kitchen SG, Dubin JA, Gottlieb MS. Initial virological and 
immunologic response to highly active antiretroviral therapy predicts 
long-term clinical outcome. Clin Infect Dis. 2001;33(4):466–472.
 18. Deeks SG. Determinants of virological response to antiretroviral 
therapy: implications for long-term strategies. Clin Infect Dis. 
2000;30(2):S177–S184.
 19. Grabar S, Pradier C, Corfec EL, et al. Factors associated with clinical 
and virological failure in patients receiving a triple therapy including 
a protease inhibitor. AIDS. 2000;14(2):141–149.
 20. Rupérez M, Pou C, Maculuve S, et al. Determinants of virological 
failure and antiretroviral drug resistance in Mozambique. J Antimicrob 
Chemother. 2015;70(9):2639–2647.
 21. Parienti JJ, Massari VR, Descamps D, et al. Predictors of viro-
logic failure and resistance in HIV-infected patients treated with 
nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 
2004;38(9):1311–1316.
 22. Zuo Z, Liang S, Sun X, et al. Drug resistance and virological failure 
among HIV-infected patients after a decade of antiretroviral treatment 
expansion in eight provinces of China. PLoS One. 2016;11(12):e0166661.
 23. Liang S, Shen Z, Yan J, et al. Low virologic failure and drug resistance 
among HIV-infected patients receiving hospital-based ART while care 
and outreach through community in Guangxi, China. Front Public 
Health. 2015;3:244.
 24. Izudi J, Alioni S, Kerukadho E, Ndungutse D. Virological failure reduced 
with HIV serostatus disclosure, extra baseline weight and rising CD4 
cells among HIV-positive adults in Northwestern Uganda. BMC Infect 
Dis. 2016;16(1):614.
 25. Rabkin JG. HIV and depression: 2008 review and update. Behav Aspects 
HIV Manag. 2008;5(4):163–171.
 
H
IV
/A
ID
S 
- R
es
ea
rc
h 
an
d 
Pa
llia
tiv
e 
Ca
re
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
21
3.
55
.7
2.
17
1 
on
 0
9-
Au
g-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
HIV/AIDS - Research and Palliative Care 2017:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
HIV/AIDS - Research and Palliative Care
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/hivaids---research-and-palliative-care-journal
HIV/AIDS - Research and Palliative Care is an international, peer-
reviewed open access journal focusing on advances in research in HIV, 
its clinical progression and management options including antiviral 
treatment, palliative care and public healthcare policies to control 
viral spread. The journal is included in PubMed. The manuscript man-
agement system is completely online and includes a very quick and fair 
peer-review system, which is all easy to use. Visit http://www.dovepress.
com/testimonials.php to read real quotes from published authors.
Dovepress
159
Determinants of virological failure among patients in Northwest Ethiopia
 
H
IV
/A
ID
S 
- R
es
ea
rc
h 
an
d 
Pa
llia
tiv
e 
Ca
re
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
21
3.
55
.7
2.
17
1 
on
 0
9-
Au
g-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
